Highlighting Unmet Needs: Real Patients, Difficult Choices Massimo Maffezzini  European Urology Supplements  Volume 8, Issue 1, Pages 4-12 (January 2009) DOI: 10.1016/j.eursup.2008.10.001 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Treatment profile of a prostate cancer patient. The changing prostate-specific antigen (PSA) profile of the patient following radical prostatectomy. A range of different androgen deprivation therapy (ADT) approaches were used sequentially in attempts to control disease with limited success. LHRH=luteinising hormone-releasing hormone; PET=positron emission tomography. European Urology Supplements 2009 8, 4-12DOI: (10.1016/j.eursup.2008.10.001) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Overall survival (OS) of hormone-refractory prostate cancer patients in docetaxel trials [24,43]: (a) OS in March 2007 after 867 deaths had occurred in the TAX327 population of 1006 patients randomly assigned to receive three-weekly (q3w) docetaxel, weekly (q1w) docetaxel, or mitoxantrone. (Reprinted with permission © 2008 American Society of Clinical Oncology. All rights reserved.); (b) OS after a median follow-up of 32 mo when 452 deaths had occurred in the Southwest Oncology Group (SWOG) 99-16 population of 674 patients randomly assigned to receive docetaxel plus estramustine or mitoxantrone plus prednisone. (Reprinted with permission © 2004 Massachusetts Medical Society. All rights reserved.) European Urology Supplements 2009 8, 4-12DOI: (10.1016/j.eursup.2008.10.001) Copyright © 2008 European Association of Urology Terms and Conditions